Cannabis and Cannabinoids (PDQ®) — summary for healthcare professionals

Introduction and clinical context

The study Cannabis and Cannabinoids (PDQ®) — summary for healthcare professionals (NCI (EUA)) is part of the scientific research on the use of cannabinoids in oncology and nausea.

In oncology, cannabinoids have historically been studied for controlling chemotherapy-induced nausea and vomiting, with systematic reviews (including Cochrane) indicating an antiemetic benefit. They are also investigated for cachexia (loss of appetite and weight) and for symptom management in supportive care. It is important to distinguish the consolidated use — symptom control and improved quality of life — from unsupported claims: there is no evidence that supports cannabis as a curative treatment for cancer.

Understanding what science shows about the use of cannabinoids in oncology and nausea helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This scientific review gathered and critically appraised the available literature on the topic. A comprehensive, updated National Cancer Institute summary on cannabis in oncology. As a synthesis of multiple studies, it offers a more robust picture than isolated reports, though it depends on the quality of the included works. For clinical practice, syntheses like this help calibrate expectations and support clinical decisions.

Mechanism of action and safety

Cannabinoids control nausea and vomiting mainly through the activation of CB1 receptors in brain areas linked to the emetic reflex, and also stimulate appetite via central pathways. In the oncology patient, often polymedicated and debilitated, safety is central: dizziness, sedation and the psychoactive effects of THC deserve attention, as do interactions with chemotherapy drugs and other symptomatic medications. Choosing the THC:CBD ratio and careful titration help balance benefit and tolerability. Use should be integrated into the oncology plan, led by the healthcare team.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (NCI (EUA)). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis cure cancer?

No. The evidence supports symptom control (nausea, appetite, pain), not curing cancer.

Does cannabis help with chemotherapy nausea?

Reviews indicate an antiemetic benefit of cannabinoids; use should be guided by the oncology team.